IOMED took part in the 2nd Annual Evidence 360: RWE, Pricing & Market Access Summit, held in London and organized by Veridon Global, bringing together leading experts across the real-world evidence (RWE) ecosystem. The event served as a key forum to discuss how real-world data is increasingly shaping decision-making across market access, pricing strategies, and health technology assessment (HTA).

Addressing one of the key challenges in RWE

During the summit, Rohit Mistry, CEO of IOMED, delivered a session focused on one of the main challenges in the field: how to unlock real-world clinical data from hospitals to generate decision-grade evidence. Accessing high-quality, structured clinical data remains a critical barrier for the effective use of RWE in research and decision-making. This challenge is particularly relevant in the context of increasing regulatory and market access demands.

Enabling access to research-ready clinical data

At IOMED, we are addressing this gap through a federated and compliant data space, designed to enable secure access to harmonized, research-ready clinical data across hospitals. By combining advanced AI technologies with robust governance frameworks, IOMED supports healthcare and life sciences stakeholders in generating high-quality evidence to inform better decisions across the product lifecycle.

Strengthening collaboration across the RWE ecosystem

The summit also provided an excellent opportunity to engage with industry leaders and peers working at the forefront of RWE, health economics, and digital health. We would like to thank Veridon Global for organizing a highly valuable event and bringing together key voices shaping the future of healthcare data and evidence generation.

‍